[go: up one dir, main page]

FR2962438B1 - Derives d'indolizines, procedes de preparation et application en therapeutique - Google Patents

Derives d'indolizines, procedes de preparation et application en therapeutique

Info

Publication number
FR2962438B1
FR2962438B1 FR1055477A FR1055477A FR2962438B1 FR 2962438 B1 FR2962438 B1 FR 2962438B1 FR 1055477 A FR1055477 A FR 1055477A FR 1055477 A FR1055477 A FR 1055477A FR 2962438 B1 FR2962438 B1 FR 2962438B1
Authority
FR
France
Prior art keywords
preparation methods
therapeutic application
indolizine derivatives
indolizine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1055477A
Other languages
English (en)
Other versions
FR2962438A1 (fr
Inventor
Chantal Alcouffe
Corentin Herbert
Gilbert Lassale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2962438(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR1055477A priority Critical patent/FR2962438B1/fr
Priority to MX2012015306A priority patent/MX2012015306A/es
Priority to US13/808,483 priority patent/US8859544B2/en
Priority to PCT/IB2011/052953 priority patent/WO2012004731A1/fr
Priority to SG10201505282YA priority patent/SG10201505282YA/en
Priority to PE2013000019A priority patent/PE20130386A1/es
Priority to ES11743363.1T priority patent/ES2552850T3/es
Priority to AU2011275426A priority patent/AU2011275426B2/en
Priority to HRP20151162TT priority patent/HRP20151162T1/hr
Priority to KR1020137002986A priority patent/KR101797795B1/ko
Priority to UAA201301382A priority patent/UA109013C2/en
Priority to SI201130644T priority patent/SI2590975T1/sl
Priority to PH1/2013/500005A priority patent/PH12013500005A1/en
Priority to HUE11743363A priority patent/HUE026067T2/en
Priority to JP2013517655A priority patent/JP5863788B2/ja
Priority to EA201291409A priority patent/EA024160B1/ru
Priority to MYPI2012005603A priority patent/MY163202A/en
Priority to EP11743363.1A priority patent/EP2590975B1/fr
Priority to PT117433631T priority patent/PT2590975E/pt
Priority to SG2012094579A priority patent/SG186436A1/en
Priority to DK11743363.1T priority patent/DK2590975T3/en
Priority to CA2805065A priority patent/CA2805065C/fr
Priority to PL11743363T priority patent/PL2590975T3/pl
Priority to BR112013000306-5A priority patent/BR112013000306A2/pt
Priority to CN201180042948.8A priority patent/CN103080112B/zh
Priority to ARP110102399A priority patent/AR082768A1/es
Priority to TW100123928A priority patent/TWI494310B/zh
Priority to UY0001033489A priority patent/UY33489A/es
Publication of FR2962438A1 publication Critical patent/FR2962438A1/fr
Application granted granted Critical
Publication of FR2962438B1 publication Critical patent/FR2962438B1/fr
Priority to TNP2012000609A priority patent/TN2012000609A1/en
Priority to DO2012000321A priority patent/DOP2012000321A/es
Priority to NI201200191A priority patent/NI201200191A/es
Priority to IL223844A priority patent/IL223844A/en
Priority to ECSP13012362 priority patent/ECSP13012362A/es
Priority to GT201300001A priority patent/GT201300001A/es
Priority to CL2013000018A priority patent/CL2013000018A1/es
Priority to ZA2013/00100A priority patent/ZA201300100B/en
Priority to CO13001349A priority patent/CO6650361A2/es
Priority to CR20130001A priority patent/CR20130001A/es
Priority to MA35638A priority patent/MA34451B1/fr
Priority to CY20151101036T priority patent/CY1116945T1/el
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
FR1055477A 2010-07-06 2010-07-06 Derives d'indolizines, procedes de preparation et application en therapeutique Expired - Fee Related FR2962438B1 (fr)

Priority Applications (40)

Application Number Priority Date Filing Date Title
FR1055477A FR2962438B1 (fr) 2010-07-06 2010-07-06 Derives d'indolizines, procedes de preparation et application en therapeutique
DK11743363.1T DK2590975T3 (en) 2010-07-06 2011-07-04 Indolizine derivatives, MANUFACTURING METHOD THEREOF AND THERAPEUTIC USE THEREOF
US13/808,483 US8859544B2 (en) 2010-07-06 2011-07-04 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
PCT/IB2011/052953 WO2012004731A1 (fr) 2010-07-06 2011-07-04 Dérivés de l'indolizine, procédé pour leur préparation, et leur utilisation thérapeutique
SG10201505282YA SG10201505282YA (en) 2010-07-06 2011-07-04 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
PE2013000019A PE20130386A1 (es) 2010-07-06 2011-07-04 Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
ES11743363.1T ES2552850T3 (es) 2010-07-06 2011-07-04 Derivados de indolizina, procedimiento para la preparación de los mismos, y sus usos terapéuticos
AU2011275426A AU2011275426B2 (en) 2010-07-06 2011-07-04 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
HRP20151162TT HRP20151162T1 (hr) 2010-07-06 2011-07-04 Derivati indolizina, postupak za njihovo pripremanje i terapijska primjena
KR1020137002986A KR101797795B1 (ko) 2010-07-06 2011-07-04 인돌리진 유도체, 그의 제조 방법 및 그의 치료 용도
UAA201301382A UA109013C2 (en) 2010-07-06 2011-07-04 INDOLISIN DERIVATIVES
SI201130644T SI2590975T1 (sl) 2010-07-06 2011-07-04 Derivati indolizina, postopek za njihovo pripravo in njihova terapevtska uporaba
PH1/2013/500005A PH12013500005A1 (en) 2010-07-06 2011-07-04 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
HUE11743363A HUE026067T2 (en) 2010-07-06 2011-07-04 Indolizine derivatives, process for their preparation and their therapeutic use
JP2013517655A JP5863788B2 (ja) 2010-07-06 2011-07-04 インドリジン誘導体、それらを調製するための方法およびそれらの治療上の使用
EA201291409A EA024160B1 (ru) 2010-07-06 2011-07-04 Производные индолизина, способ их получения и их терапевтическое применение
MYPI2012005603A MY163202A (en) 2010-07-06 2011-07-04 Indolizine derivatives, proces for the preparation thereof and therapeutic use thereof
EP11743363.1A EP2590975B1 (fr) 2010-07-06 2011-07-04 Dérivés de l'indolizine, procédé pour leur préparation, et leur utilisation thérapeutique
PT117433631T PT2590975E (pt) 2010-07-06 2011-07-04 Derivados de indolizina, processo de preparação dos mesmos e utilização terapêutica dos mesmos
SG2012094579A SG186436A1 (en) 2010-07-06 2011-07-04 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
MX2012015306A MX2012015306A (es) 2010-07-06 2011-07-04 Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica.
PL11743363T PL2590975T3 (pl) 2010-07-06 2011-07-04 Pochodne indolizyny, sposób ich wytwarzania i ich zastosowanie terapeutyczne
BR112013000306-5A BR112013000306A2 (pt) 2010-07-06 2011-07-04 derivados de indolizina, processo para a preparação dos mesmos e uso terapêutico dos mesmos
CA2805065A CA2805065C (fr) 2010-07-06 2011-07-04 Derives de l'indolizine, procede pour leur preparation, et leur utilisation therapeutique
CN201180042948.8A CN103080112B (zh) 2010-07-06 2011-07-04 吲嗪衍生物，其制备方法及其治疗用途
ARP110102399A AR082768A1 (es) 2010-07-06 2011-07-05 Derivados de indolizina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen
TW100123928A TWI494310B (zh) 2010-07-06 2011-07-06 吲嗪衍生物、其製備方法及其治療用途
UY0001033489A UY33489A (es) 2010-07-06 2011-07-06 Derivados de indolizina, su procediemiento de preparacion y su aplicacion en terapeutica
TNP2012000609A TN2012000609A1 (en) 2010-07-06 2012-12-19 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof
NI201200191A NI201200191A (es) 2010-07-06 2012-12-20 Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
DO2012000321A DOP2012000321A (es) 2010-07-06 2012-12-20 Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
IL223844A IL223844A (en) 2010-07-06 2012-12-24 History of indolysin, a process for their preparation and medical use
GT201300001A GT201300001A (es) 2010-07-06 2013-01-02 Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
ECSP13012362 ECSP13012362A (es) 2010-07-06 2013-01-02 Derivados de indolizina, su procedimiento de preparación
CL2013000018A CL2013000018A1 (es) 2010-07-06 2013-01-03 Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
ZA2013/00100A ZA201300100B (en) 2010-07-06 2013-01-04 Indolizine derivatives,process for the preparation thereof and therapeutic use thereof
CO13001349A CO6650361A2 (es) 2010-07-06 2013-01-04 Derivados de indolizina, su procedimiento de preparacion y su aplicacion en terapeutica
CR20130001A CR20130001A (es) 2010-07-06 2013-01-07 Derivados de indolizina, su procedimiento de preparación y su aplicación en terapéutica
MA35638A MA34451B1 (fr) 2010-07-06 2013-02-05 Dérivés de l'indolizine, procédé pour leur préparation, et leur utilisation thérapeutique
CY20151101036T CY1116945T1 (el) 2010-07-06 2015-11-18 Παραγωγα ινδολιζινης, διεργασια για την παρασκευη αυτης και θεραπευτικη χρηση αυτης

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1055477A FR2962438B1 (fr) 2010-07-06 2010-07-06 Derives d'indolizines, procedes de preparation et application en therapeutique

Publications (2)

Publication Number Publication Date
FR2962438A1 FR2962438A1 (fr) 2012-01-13
FR2962438B1 true FR2962438B1 (fr) 2012-08-17

Family

ID=43382527

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1055477A Expired - Fee Related FR2962438B1 (fr) 2010-07-06 2010-07-06 Derives d'indolizines, procedes de preparation et application en therapeutique

Country Status (39)

Country Link
US (1) US8859544B2 (fr)
EP (1) EP2590975B1 (fr)
JP (1) JP5863788B2 (fr)
KR (1) KR101797795B1 (fr)
CN (1) CN103080112B (fr)
AR (1) AR082768A1 (fr)
AU (1) AU2011275426B2 (fr)
BR (1) BR112013000306A2 (fr)
CA (1) CA2805065C (fr)
CL (1) CL2013000018A1 (fr)
CO (1) CO6650361A2 (fr)
CR (1) CR20130001A (fr)
CY (1) CY1116945T1 (fr)
DK (1) DK2590975T3 (fr)
DO (1) DOP2012000321A (fr)
EA (1) EA024160B1 (fr)
EC (1) ECSP13012362A (fr)
ES (1) ES2552850T3 (fr)
FR (1) FR2962438B1 (fr)
GT (1) GT201300001A (fr)
HR (1) HRP20151162T1 (fr)
HU (1) HUE026067T2 (fr)
IL (1) IL223844A (fr)
MA (1) MA34451B1 (fr)
MX (1) MX2012015306A (fr)
MY (1) MY163202A (fr)
NI (1) NI201200191A (fr)
PE (1) PE20130386A1 (fr)
PH (1) PH12013500005A1 (fr)
PL (1) PL2590975T3 (fr)
PT (1) PT2590975E (fr)
SG (2) SG10201505282YA (fr)
SI (1) SI2590975T1 (fr)
TN (1) TN2012000609A1 (fr)
TW (1) TWI494310B (fr)
UA (1) UA109013C2 (fr)
UY (1) UY33489A (fr)
WO (1) WO2012004731A1 (fr)
ZA (1) ZA201300100B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
FR2985258A1 (fr) * 2011-12-28 2013-07-05 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
WO2014026125A1 (fr) 2012-08-10 2014-02-13 Incyte Corporation Dérivés de pyrazine en tant qu'inhibiteurs de fgfr
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
EA035095B1 (ru) 2013-04-19 2020-04-27 Инсайт Холдингс Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US10435402B2 (en) * 2015-01-08 2019-10-08 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EA038045B1 (ru) 2015-02-20 2021-06-28 Инсайт Корпорейшн Бициклические гетероциклы в качестве ингибиторов fgfr
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US11253521B2 (en) 2015-09-25 2022-02-22 Ludwig Institute For Cancer Research Ltd 3-hydroxy-quinazoline-2,4-dione derivatives and their use as nuclease modulators
CN106045994A (zh) * 2016-06-12 2016-10-26 上海大学 全氟烷基吲嗪衍生物及其合成方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (fr) 2019-03-08 2020-09-17 Incyte Corporation Méthodes de traitement du cancer au moyen d'un inhibiteur de fgfr
WO2021007269A1 (fr) 2019-07-09 2021-01-14 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021067374A1 (fr) 2019-10-01 2021-04-08 Incyte Corporation Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
PH12022550892A1 (en) 2019-10-14 2023-05-03 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
EP4069696A1 (fr) 2019-12-04 2022-10-12 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP2024513575A (ja) 2021-04-12 2024-03-26 インサイト・コーポレイション Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
WO2022261160A1 (fr) 2021-06-09 2022-12-15 Incyte Corporation Hétérocycles tricycliques en tant qu'inhibiteurs de fgfr

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116462A1 (en) 2002-12-12 2004-06-17 Mitsunori Ono Indolizine compounds
ATE370145T1 (de) 2002-04-03 2007-09-15 Bristol Myers Squibb Co Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
FR2838123B1 (fr) * 2002-04-04 2005-06-10 Sanofi Synthelabo Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
FR2859997B1 (fr) 2003-09-18 2006-02-03 Sanofi Synthelabo Nouveaux derives d'indolizine 1,2,3,6,7,8 substituee, inhibiteurs des fgfs, leur procede de preparation et les compositions pharmaceutiques les contenant.
KR20060121878A (ko) 2003-09-25 2006-11-29 얀센 파마슈티카 엔.브이. Ｈｉｖ를 저해하는 퓨린 유도체
FR2865934B1 (fr) 2004-02-05 2006-05-05 Sanofi Synthelabo Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
FR2893616B1 (fr) 2005-11-23 2008-01-04 Sanofi Aventis Sa Nouveaux derives d'indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
FR2896247B1 (fr) * 2006-01-13 2008-02-29 Sanofi Aventis Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
EP1891955A1 (fr) * 2006-07-24 2008-02-27 Sanofi-Aventis Utilisation de dérivés de indolizines, inhibiteurs de FGF, pour la préparation d'un médicament pour le traitement d'affections dégénératives des articulations

Also Published As

Publication number Publication date
NI201200191A (es) 2013-05-13
CN103080112B (zh) 2016-04-20
US8859544B2 (en) 2014-10-14
PT2590975E (pt) 2015-11-24
FR2962438A1 (fr) 2012-01-13
CY1116945T1 (el) 2017-04-05
ZA201300100B (en) 2014-03-26
BR112013000306A2 (pt) 2020-08-04
AU2011275426A1 (en) 2013-01-24
US20130116249A1 (en) 2013-05-09
MA34451B1 (fr) 2013-08-01
DOP2012000321A (es) 2013-04-15
TN2012000609A1 (en) 2014-04-01
PH12013500005A1 (en) 2013-02-18
CN103080112A (zh) 2013-05-01
SG186436A1 (en) 2013-01-30
EA201291409A1 (ru) 2013-05-30
CO6650361A2 (es) 2013-04-15
MY163202A (en) 2017-08-15
CA2805065C (fr) 2018-07-03
SI2590975T1 (sl) 2015-12-31
HRP20151162T1 (hr) 2015-12-04
CA2805065A1 (fr) 2012-01-12
PE20130386A1 (es) 2013-04-11
DK2590975T3 (en) 2015-12-07
AR082768A1 (es) 2013-01-09
TW201206931A (en) 2012-02-16
TWI494310B (zh) 2015-08-01
ECSP13012362A (es) 2013-01-31
UY33489A (es) 2012-01-31
WO2012004731A1 (fr) 2012-01-12
CR20130001A (es) 2013-02-05
EP2590975B1 (fr) 2015-08-19
PL2590975T3 (pl) 2016-01-29
KR101797795B1 (ko) 2017-11-15
SG10201505282YA (en) 2015-08-28
EA024160B1 (ru) 2016-08-31
AU2011275426B2 (en) 2016-05-12
HUE026067T2 (en) 2016-05-30
MX2012015306A (es) 2013-04-29
JP2013530210A (ja) 2013-07-25
GT201300001A (es) 2014-04-29
EP2590975A1 (fr) 2013-05-15
JP5863788B2 (ja) 2016-02-17
KR20130128362A (ko) 2013-11-26
IL223844A (en) 2016-03-31
ES2552850T3 (es) 2015-12-02
UA109013C2 (en) 2015-07-10
CL2013000018A1 (es) 2013-05-10

Similar Documents

Publication Publication Date Title
FR2962438B1 (fr) Derives d'indolizines, procedes de preparation et application en therapeutique
FR2962437B1 (fr) Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
FR2963007B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
FR2915198B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
HUE046216T2 (hu) 1H-pirazolo [3,4-b]piridin-származékok és terápiás alkalmazásuk
DK2600719T3 (da) 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
FR2953520B1 (fr) Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
FR2933700B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2945534B1 (fr) DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2943669B1 (fr) Derives de nicotinamide,leur preparation et leur application en therapeutique
FR2967674B1 (fr) Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine
FR2952934B1 (fr) Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2915197B1 (fr) Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
FR2954943B1 (fr) Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2925902B1 (fr) DERIVES D'IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2917413B1 (fr) Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2955109B1 (fr) Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
FR2925901B1 (fr) DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2940284B1 (fr) Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
FR2925903B1 (fr) DERIVES 6-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2925906B1 (fr) COMPOSES DE N-PHENYL-IMIDAZO°1,2-a!PYRIDINE-2-CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2986232B1 (fr) Derives heterocycliques bicycliques, leur preparation et leur application en therapeutique
FR2925907B1 (fr) DERIVES DE 2-HETEROAROYL-IMIDAZO°1,2-a!PYRIDINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20170331